Click-cleavable imaging in HER2-positive cancers (CleavHER trial).

2025-520673-39-00 Protocol 116650 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 2 Apr 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 116650

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 28
Countries 1
Sites 1

HER2-positive tumors

Key facts

Sponsor
Radboud universitair medisch centrum Stichting
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01], Diseases [C] - Neoplasms [C04]
Trial duration
2 Apr 2026 → ongoing
Decision date (initial)
2025-08-07
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-520673-39-00
ClinicalTrials.gov
NCT07009184

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

HER2-positive tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Radboud universitair medisch centrum Stichting

Sponsor organisation
Radboud universitair medisch centrum Stichting
Address
Geert Grooteplein Zuid 10
City
Nijmegen
Postcode
6525 GA
Country
Netherlands

Scientific contact point

Organisation
Radboud universitair medisch centrum Stichting
Contact name
James Nagarajah

Public contact point

Organisation
Radboud universitair medisch centrum Stichting
Contact name
Medical Imaging Research Office

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 28 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Radboud universitair medisch centrum Stichting
Medical Imaging, Nuclear Medicine, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-04-02 2026-04-02

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-05-06 Netherlands Acceptable with conditions
2025-08-07
2025-08-07
2 SUBSTANTIAL MODIFICATION SM-1 2025-08-21 Netherlands Acceptable
2025-10-06
2025-10-06
3 SUBSTANTIAL MODIFICATION SM-2 2025-12-17 Netherlands Acceptable
2026-03-23
2026-03-25